Sofinnova Partners Leads Inventiva Pharma €35,5 M Capital Increase
Sofinnova Partners, a leading European venture capital firm specialized in Life Sciences, announced today it has led Inventiva Pharma (IVA) €35,5 M capital increase through its newly created Sofinnova Crossover I Fund. Sofinnova Partners invested €10 M, becoming one of the company’s largest investors.
Inventiva, listed on Euronext Paris (IVA), is a biopharmaceutical company specialized in the development of treatments for fibroticand orphan diseases, such as Non Alcoholic Steato Hepatitis (NASH), systemic scleroderma (SSc) and mucopolysaccharidosis (MPS). Inventiva has a strong technology platform built on its extensive knowledge of the mechanisms of fibrosis, a chemical library of over 240,000 molecules and cell models, including patient cells, helping accelerate the discovery of new mechanisms and therapeutic candidates for the treatment of fibrotic diseases, orphan diseases and cancers.
Funds raised will allow Inventiva to advance its portfolio of compounds in the clinic, in particular its lead compound, lanifibranor, through preparatory studies towards a Phase III trial for the treatment of NASH, a growing liver disease that affects more than 30 million people in the United States, and of systemic sclerosis an orphan disease with high unmet medical needs. Funds will also allow Inventiva to advance its second program, odiparcil, a drug candidate for the treatment of multiple forms of mucopolysaccharidosis.
Jacques Theurillat, Partner in the Sofinnova Crossover I Fund, commented: « Inventiva is exactly the type of company we are seeking to invest in with our Crossover fund: innovative technology addressing diseases of high unmet medical need with large market sizes, an experimented team backed by a prestigious international investor syndicate helping the company develop its global ambitions ».
Press for Sofinnova Partners
Anne Rein, +33 6 03 35 92 05
Information om Business Wire
101 California Street, 20th Floor
CA 94111 San Francisco
Følg pressemeddelelser fra Business Wire
Skriv dig op her og modtag pressemeddelelser på mail. Indtast din mail, klik på abonner og følg instruktionerne i den udsendte mail.
Flere pressemeddelelser fra Business Wire
HCL-TECHNOLOGIES16.8.2018 21:04 | pressemeddelelse
Manchester United Shoots for Success with a “Digital Experience Platform” Powered by HCL
IBC16.8.2018 19:43 | pressemeddelelse
4K 4Charity Fun Run Announces Open Registration for IBC2018
AIAS/D.I.C.E.-CANNES16.8.2018 16:03 | pressemeddelelse
2018 D.I.C.E. Cannes Announced Round 3 Speakers
GN-HEARING16.8.2018 15:02 | pressemeddelelse
GN Hearing and Google Announce Partnership to Bring Direct Mobile Streaming from Android Devices to Hearing Aids
CA-GUIDEWIRE-SOFTWARE16.8.2018 14:57 | pressemeddelelse
Zurich Expands Global Use of Guidewire InsurancePlatform with Selection of Guidewire Cyence Risk Analytics
CA-SCIENTIST.COM16.8.2018 14:08 | pressemeddelelse
Scientist.com Named One of America’s Ten Fastest-Growing Private Companies by Inc. Magazine
I vores nyhedsrum kan du læse alle vores pressemeddelelser, tilgå materiale i form af billeder og dokumenter, og finde vores kontaktoplysninger.Besøg vores nyhedsrum